Jan. 15, 2025 — Most treatments being pursued today to protect against Alzheimer'sdisease focus on amyloid plaques and tau tangles that accumulate in the brain, but new research points to a ...
The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...
It should come as no surprise that Alzheimer’s has touched ... living with the disease. By 2060, that number is projected to grow to nearly 14 million — doubling the current total ...
Former study was recently accepted in a peer-reviewed medical journal with focus on Alzheimer’sdisease titled, “Blarcamesine for the treatment ... based on current information and ...
Alzheimer'sdisease is the most common form of dementia, affecting more than three million Americans per year. And while its exact cause is unknown, researchers may have just had a breakthrough.